Dawnrays Pharmaceutical (Holdings) Limited

SEHK:2348 Stock Report

Market Cap: HK$1.8b

Dawnrays Pharmaceutical (Holdings) Management

Management criteria checks 2/4

Dawnrays Pharmaceutical (Holdings)'s CEO is Weixian Wu, appointed in Feb 2022, has a tenure of 2.08 years. total yearly compensation is CN¥3.09M, comprised of 58.1% salary and 41.9% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth HK$2.34M. The average tenure of the management team and the board of directors is 17.5 years and 15.9 years respectively.

Key information

Weixian Wu

Chief executive officer

CN¥3.1m

Total compensation

CEO salary percentage58.1%
CEO tenure2.1yrs
CEO ownership0.1%
Management average tenure17.5yrs
Board average tenure15.9yrs

Recent management updates

Recent updates

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Mar 25
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Aug 30
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

May 26
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Apr 04
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 19
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Sep 22
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Sep 12
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Aug 29
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Feb 28
Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Feb 07
Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Jan 14
Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Dec 22
Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Dec 09
What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Nov 23
Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

CEO Compensation Analysis

How has Weixian Wu's remuneration changed compared to Dawnrays Pharmaceutical (Holdings)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

CN¥326m

Sep 30 2023n/an/a

CN¥384m

Jun 30 2023n/an/a

CN¥442m

Mar 31 2023n/an/a

CN¥400m

Dec 31 2022CN¥3mCN¥2m

CN¥358m

Compensation vs Market: Weixian's total compensation ($USD426.96K) is above average for companies of similar size in the Hong Kong market ($USD319.87K).

Compensation vs Earnings: Insufficient data to compare Weixian's compensation with company performance.


CEO

Weixian Wu (54 yo)

2.1yrs

Tenure

CN¥3,086,000

Compensation

Mr. Weixian Wu serves as Chief Executive Officer of Dawnrays Pharmaceutical (Holdings) Limited since February 16, 2022. He joined Nanjing PharmaRays Science and Technology Co., Ltd., a non-wholly owned sub...


Leadership Team

NamePositionTenureCompensationOwnership
Kei Ling Li
Co-Founder & Executive Chairman21.4yrsCN¥999.00k7.16%
CN¥ 125.6m
Weixian Wu
Chief Executive Officer2.1yrsCN¥3.09m0.13%
CN¥ 2.3m
Yung Lai Hung
Co-Founder & Executive Director29.2yrsCN¥638.00k0.13%
CN¥ 2.2m
Yi Jun Wu
Chief Financial Officer5.9yrsno datano data
Kit Ling Pang
Company Secretaryno datano datano data

17.5yrs

Average Tenure

59yo

Average Age

Experienced Management: 2348's management team is seasoned and experienced (17.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kei Ling Li
Co-Founder & Executive Chairman21.4yrsCN¥999.00k7.16%
CN¥ 125.6m
Yung Lai Hung
Co-Founder & Executive Director21.4yrsCN¥638.00k0.13%
CN¥ 2.2m
Hao Xi Ede
Independent Non-Executive Director8.8yrsCN¥309.00kno data
Hong Man Leung
Non-Executive Director18.3yrsCN¥258.00kno data
Tung Sing Lo
Independent Non-Executive Director13.4yrsCN¥309.00kno data
Ming Yee Lam
Independent Non-Executive Director5.8yrsCN¥309.00kno data

15.9yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 2348's board of directors are seasoned and experienced ( 15.9 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.